Effects of Dietary Oltipraz and Ethoxyquin on Aflatoxin B1 Biotransformation in Non-Human Primates
Authors:
Open Access
- 1 March 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 54 (1) , 30-41
Abstract
Following aflatoxin B1 (AFB) exposure, rats readily develop liver tumors. However, treatment of rats with a variety of compounds, including the synthetic dithiolthione oltipraz and the antioxidant ethoxyquin, protects these rodents from AFB-induced hepatocarcinogenesis. Several epidemiological studies strongly suggest that AFB is also a causative agent of liver cancer in humans. However, relatively little is known about the efficacy of cancer chemoprevention in human and non-human primates. To this end, we examined the effects of chemopreventive agents on AFB metabolism in non-human primates. Hepatic aflatoxin B1 metabolism profiles of macaque (Macaca nemestrina) and marmoset (Callithrix jacchus) monkeys were determined and compared to humans. Quantitatively, the oxidative metabolism of this mycotoxin was similar in the three primate species. In contrast to macaques, both humans and marmosets lacked AFB-glutathione conjugating activity. It was concluded that marmosets resembled human AFB metabolism more closely than the macaques, and therefore, marmoset monkeys were chosen for this study. Eleven adult male marmosets were randomly assigned to three groups. Animals received the synthetic dithiolthione oltipraz, the antioxidant ethoxyquin, or vehicle only. In addition, two single doses of AFB were also administered orally before and after animals were treated with aforementioned compounds. Both oltipraz and ethoxyquin induced aflatoxin B1-glutathione conjugating activity in the livers of some but not all marmosets. In addition, 10 μM oltipraz inhibited cytochrome P450-mediated activation of AFB to the ultimate carcinogenic metabolite, aflatoxin B1-8,9-epoxide,in vitro, up to 51%. Furthermore, animals treated in vivo with oltipraz, but not ethoxyquin, exhibited a significant reduction (53% average) in AFB-DNA adduct formation relative to the control animals (p < 0.05). Together, our data suggest that chemoprevention is also effective in primates; however, most likely to a lesser degree than in rodents.Keywords
This publication has 36 references indexed in Scilit:
- The Kinetics of Aflatoxin B1Oxidation by Human cDNA-Expressed and Human Liver Microsomal Cytochromes P450 1A2 and 3A4Toxicology and Applied Pharmacology, 1996
- Cellular interactions and metabolism of aflatoxin: An updatePharmacology & Therapeutics, 1995
- Bioactivation of aflatoxin B1 by human liver microsomes: Role of cytochrome P450 IIIA enzymesToxicology and Applied Pharmacology, 1991
- Contribution of the glutathione S-transferases to the mechanisms of resistance to aflatoxin B1Pharmacology & Therapeutics, 1991
- Molecular dosimetry of hepatic aflatoxin B1-DNA adducts: Linear correlation with hepatic cancer riskRegulatory Toxicology and Pharmacology, 1989
- Effects of modulation of hepatic glutathione on biotransformation and covalent binding of aflatoxin B1 to DNA in the mouseToxicology and Applied Pharmacology, 1988
- Comparative effects of butylated hydroxyanisole on hepatic in vivo DNA binding and in vitro biotransformation of aflatoxin B1 in the rat and mouseToxicology and Applied Pharmacology, 1987
- The metabolism of aflatoxin B1 by human liverBiochemical Pharmacology, 1985
- The inhibitory effects of ethoxyquin on the carcinogenic action of aflatoxin B1 in ratsCancer Letters, 1983
- Metabolism of aflatoxin B1 in cultured mouse hepatocytes: Comparison with rat and effects of cyclohexene oxide and diethyl maleateToxicology and Applied Pharmacology, 1979